Overall, our findings suggest that the TIP60/KIAA1429/KDM5B/FoxO1 axis is involved in immune evasion of HCC cells, and targeting this pathway may be a promising therapeutic strategy for treating HCC. Here, VIRMA is linked to hepatocellular carcinoma.